Intensity of MRI gadolinium enhancement in cerebral adrenoleukodystrophy: A biomarker for inflammation and predictor of outcome following transplantation in higher risk patients

W. P. Miller, L. F. Mantovani, J. Muzic, J. B. Rykken, R. S. Gawande, T. C. Lund, R. M. Shanley, G. V. Raymond, P. J. Orchard, D. R. Nascene

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Background and Purpose: Outcomes following hematopoietic stem cell transplantation for higher risk childhood-onset cerebral adrenoleukodystrophy are variable. We explored whether a brain MR imaging gadolinium intensity scoring system improves prediction of neurologic outcome. Materials and Methods: We developed a 4-point scale of gadolinium intensity relative to the choroid plexus: 0=no enhancement; 1 = hypointense; 2 = isointense; 3 = hyperintense. The interobserver concordance of the scale was assessed on 30 randomly chosen studies. Scores were generated for 64 evaluable patients and compared with CSF chitotriosidase levels, a known inflammatory marker correlating with outcomes following transplantation. For 25 evaluable higher risk patients (Loes =10), the gadolinium intensity score was compared with longer term posttransplantation clinical change. RESULTS: The gadolinium intensity scoring system showed good interobserver reproducibility (κ=0.72). Of 64 evaluable boys, the score positively correlated with average concomitant CSF chitotriosidase activity in nanograms/milliliter/hour: 0: 2717, n = 5; 1: 3218, n = 13; 2: 6497, n = 23; and 3: 12,030, n = 23 (P κ.01). For 25 evaluable higher risk patients, more intense pretransplantation brain MR imaging gadolinium enhancement predicted greater average loss on the adrenoleukodystrophy neurologic function scale following transplantation: 0/1: adrenoleukodystrophy neurologic function scale score difference = 4.3, n = 7; 2/3: adrenoleukodystrophy neurologic function scale score difference = 10.4, n = 18 (P =.05). Conclusions: Gadolinium enhancement intensity on brain MR imaging can be scored simply and reproducibly for cerebral adrenoleukodystrophy. The enhancement score significantly correlates with chitotriosidase. In boys with higher risk cerebral disease (Loes =10), the enhancement score itself predicts neurologic outcome following treatment. Such data may help guide treatment decisions for clinicians and families.

Original languageEnglish (US)
Pages (from-to)367-372
Number of pages6
JournalAmerican Journal of Neuroradiology
Volume37
Issue number2
DOIs
StatePublished - Feb 2016

Fingerprint

Adrenoleukodystrophy
Gadolinium
Nervous System
Transplantation
Biomarkers
Inflammation
Neuroimaging
Choroid Plexus
Hematopoietic Stem Cell Transplantation
chitotriosidase

All Science Journal Classification (ASJC) codes

  • Radiology Nuclear Medicine and imaging
  • Clinical Neurology

Cite this

Miller, W. P. ; Mantovani, L. F. ; Muzic, J. ; Rykken, J. B. ; Gawande, R. S. ; Lund, T. C. ; Shanley, R. M. ; Raymond, G. V. ; Orchard, P. J. ; Nascene, D. R. / Intensity of MRI gadolinium enhancement in cerebral adrenoleukodystrophy : A biomarker for inflammation and predictor of outcome following transplantation in higher risk patients. In: American Journal of Neuroradiology. 2016 ; Vol. 37, No. 2. pp. 367-372.
@article{f186ab51595641249721729438ee7bd6,
title = "Intensity of MRI gadolinium enhancement in cerebral adrenoleukodystrophy: A biomarker for inflammation and predictor of outcome following transplantation in higher risk patients",
abstract = "Background and Purpose: Outcomes following hematopoietic stem cell transplantation for higher risk childhood-onset cerebral adrenoleukodystrophy are variable. We explored whether a brain MR imaging gadolinium intensity scoring system improves prediction of neurologic outcome. Materials and Methods: We developed a 4-point scale of gadolinium intensity relative to the choroid plexus: 0=no enhancement; 1 = hypointense; 2 = isointense; 3 = hyperintense. The interobserver concordance of the scale was assessed on 30 randomly chosen studies. Scores were generated for 64 evaluable patients and compared with CSF chitotriosidase levels, a known inflammatory marker correlating with outcomes following transplantation. For 25 evaluable higher risk patients (Loes =10), the gadolinium intensity score was compared with longer term posttransplantation clinical change. RESULTS: The gadolinium intensity scoring system showed good interobserver reproducibility (κ=0.72). Of 64 evaluable boys, the score positively correlated with average concomitant CSF chitotriosidase activity in nanograms/milliliter/hour: 0: 2717, n = 5; 1: 3218, n = 13; 2: 6497, n = 23; and 3: 12,030, n = 23 (P κ.01). For 25 evaluable higher risk patients, more intense pretransplantation brain MR imaging gadolinium enhancement predicted greater average loss on the adrenoleukodystrophy neurologic function scale following transplantation: 0/1: adrenoleukodystrophy neurologic function scale score difference = 4.3, n = 7; 2/3: adrenoleukodystrophy neurologic function scale score difference = 10.4, n = 18 (P =.05). Conclusions: Gadolinium enhancement intensity on brain MR imaging can be scored simply and reproducibly for cerebral adrenoleukodystrophy. The enhancement score significantly correlates with chitotriosidase. In boys with higher risk cerebral disease (Loes =10), the enhancement score itself predicts neurologic outcome following treatment. Such data may help guide treatment decisions for clinicians and families.",
author = "Miller, {W. P.} and Mantovani, {L. F.} and J. Muzic and Rykken, {J. B.} and Gawande, {R. S.} and Lund, {T. C.} and Shanley, {R. M.} and Raymond, {G. V.} and Orchard, {P. J.} and Nascene, {D. R.}",
year = "2016",
month = "2",
doi = "10.3174/ajnr.A4500",
language = "English (US)",
volume = "37",
pages = "367--372",
journal = "American Journal of Neuroradiology",
issn = "0195-6108",
publisher = "American Society of Neuroradiology",
number = "2",

}

Intensity of MRI gadolinium enhancement in cerebral adrenoleukodystrophy : A biomarker for inflammation and predictor of outcome following transplantation in higher risk patients. / Miller, W. P.; Mantovani, L. F.; Muzic, J.; Rykken, J. B.; Gawande, R. S.; Lund, T. C.; Shanley, R. M.; Raymond, G. V.; Orchard, P. J.; Nascene, D. R.

In: American Journal of Neuroradiology, Vol. 37, No. 2, 02.2016, p. 367-372.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Intensity of MRI gadolinium enhancement in cerebral adrenoleukodystrophy

T2 - A biomarker for inflammation and predictor of outcome following transplantation in higher risk patients

AU - Miller, W. P.

AU - Mantovani, L. F.

AU - Muzic, J.

AU - Rykken, J. B.

AU - Gawande, R. S.

AU - Lund, T. C.

AU - Shanley, R. M.

AU - Raymond, G. V.

AU - Orchard, P. J.

AU - Nascene, D. R.

PY - 2016/2

Y1 - 2016/2

N2 - Background and Purpose: Outcomes following hematopoietic stem cell transplantation for higher risk childhood-onset cerebral adrenoleukodystrophy are variable. We explored whether a brain MR imaging gadolinium intensity scoring system improves prediction of neurologic outcome. Materials and Methods: We developed a 4-point scale of gadolinium intensity relative to the choroid plexus: 0=no enhancement; 1 = hypointense; 2 = isointense; 3 = hyperintense. The interobserver concordance of the scale was assessed on 30 randomly chosen studies. Scores were generated for 64 evaluable patients and compared with CSF chitotriosidase levels, a known inflammatory marker correlating with outcomes following transplantation. For 25 evaluable higher risk patients (Loes =10), the gadolinium intensity score was compared with longer term posttransplantation clinical change. RESULTS: The gadolinium intensity scoring system showed good interobserver reproducibility (κ=0.72). Of 64 evaluable boys, the score positively correlated with average concomitant CSF chitotriosidase activity in nanograms/milliliter/hour: 0: 2717, n = 5; 1: 3218, n = 13; 2: 6497, n = 23; and 3: 12,030, n = 23 (P κ.01). For 25 evaluable higher risk patients, more intense pretransplantation brain MR imaging gadolinium enhancement predicted greater average loss on the adrenoleukodystrophy neurologic function scale following transplantation: 0/1: adrenoleukodystrophy neurologic function scale score difference = 4.3, n = 7; 2/3: adrenoleukodystrophy neurologic function scale score difference = 10.4, n = 18 (P =.05). Conclusions: Gadolinium enhancement intensity on brain MR imaging can be scored simply and reproducibly for cerebral adrenoleukodystrophy. The enhancement score significantly correlates with chitotriosidase. In boys with higher risk cerebral disease (Loes =10), the enhancement score itself predicts neurologic outcome following treatment. Such data may help guide treatment decisions for clinicians and families.

AB - Background and Purpose: Outcomes following hematopoietic stem cell transplantation for higher risk childhood-onset cerebral adrenoleukodystrophy are variable. We explored whether a brain MR imaging gadolinium intensity scoring system improves prediction of neurologic outcome. Materials and Methods: We developed a 4-point scale of gadolinium intensity relative to the choroid plexus: 0=no enhancement; 1 = hypointense; 2 = isointense; 3 = hyperintense. The interobserver concordance of the scale was assessed on 30 randomly chosen studies. Scores were generated for 64 evaluable patients and compared with CSF chitotriosidase levels, a known inflammatory marker correlating with outcomes following transplantation. For 25 evaluable higher risk patients (Loes =10), the gadolinium intensity score was compared with longer term posttransplantation clinical change. RESULTS: The gadolinium intensity scoring system showed good interobserver reproducibility (κ=0.72). Of 64 evaluable boys, the score positively correlated with average concomitant CSF chitotriosidase activity in nanograms/milliliter/hour: 0: 2717, n = 5; 1: 3218, n = 13; 2: 6497, n = 23; and 3: 12,030, n = 23 (P κ.01). For 25 evaluable higher risk patients, more intense pretransplantation brain MR imaging gadolinium enhancement predicted greater average loss on the adrenoleukodystrophy neurologic function scale following transplantation: 0/1: adrenoleukodystrophy neurologic function scale score difference = 4.3, n = 7; 2/3: adrenoleukodystrophy neurologic function scale score difference = 10.4, n = 18 (P =.05). Conclusions: Gadolinium enhancement intensity on brain MR imaging can be scored simply and reproducibly for cerebral adrenoleukodystrophy. The enhancement score significantly correlates with chitotriosidase. In boys with higher risk cerebral disease (Loes =10), the enhancement score itself predicts neurologic outcome following treatment. Such data may help guide treatment decisions for clinicians and families.

UR - http://www.scopus.com/inward/record.url?scp=84957991350&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84957991350&partnerID=8YFLogxK

U2 - 10.3174/ajnr.A4500

DO - 10.3174/ajnr.A4500

M3 - Article

C2 - 26427835

AN - SCOPUS:84957991350

VL - 37

SP - 367

EP - 372

JO - American Journal of Neuroradiology

JF - American Journal of Neuroradiology

SN - 0195-6108

IS - 2

ER -